Details of the Drug Combinations

General Information of This Drug (ID: DM3WP0N)

Drug Name

AL3818 DM3WP0N

Synonyms

Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-

Indication

Disease Entry	ICD 11	Status	REF
Alveolar soft part sarcoma	2A60-2C35	Phase 3	[1]
Leiomyosarcoma	2B58	Phase 3	[1]
Synovial sarcoma	2B5A	Phase 3	[1]
Cervical cancer	2C77.0	Phase 1/2	[1]
Endometrial cancer	2C76	Phase 1/2	[1]
Fallopian tube cancer	2C74	Phase 1/2	[1]
Ovarian cancer	2C73	Phase 1/2	[1]
Peritoneal cavity cancer	2C51.Z	Phase 1/2	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Al3818 + Panobinostat	DC3RQZX	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

17 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Al3818 + Docetaxel	DCI5JZH	Docetaxel	Non-squamous Non-small Cell Lung Cancer	[3]
Al3818 + Pemetrexed	DCN7DHO	Pemetrexed	Non-squamous Non-small Cell Lung Cancer	[3]
Al3818 + Irinotecan	DCE7HDT	Irinotecan	Ewing's Tumor Metastatic	[4]
Al3818 + Osimertinib	DCJB3F7	Osimertinib	Non-Small Cell Lung Cancer With EGFR Mutation	[5]
Al3818 + MK-4827	DCSZQXT	MK-4827	HER2-negative Breast Cancer	[6]
Gefitinib + Al3818	DCEQAP5	Gefitinib	Non-Small-Cell Lung	[7]
Gefitinib + Al3818	DCORLUW	Gefitinib	Non-squamous Non-small Cell Lung Cancer	[8]
Trametinib + Al3818	DCNXY1R	Trametinib	Non Small Cell Lung Cancer	[9]
Al3818 + Oxaliplatin	DCPJCJW	Oxaliplatin	Colorectal Cancer	[10]
Al3818 + Olaparib	DCEUU6U	Olaparib	Ovarian Cancer	[11]
Al3818 + Temozolomide	DCGQUMB	Temozolomide	Glioblastoma	[12]
Al3818 + MK-4827	DCW428S	MK-4827	Platinum-resistant Ovarian Cancer	[13]
Al3818 + Capecitabine	DCZNDX4	Capecitabine	Metastatic Triple-Negative Breast Cancer	[14]
Eribulin + Al3818	DCQS7O6	Eribulin	HER2-negative Breast Cancer	[15]
Al3818 + Icotinib hydrochloride	DCB0F43	Icotinib hydrochloride	Non Small Cell Lung Cancer	[16]
Al3818 + Topotecan	DCUXKE6	Topotecan	Small Cell Lung Cancer	[17]
Gefitinib + Al3818	DCBHRAJ	Gefitinib	Lung Cancer, Nonsmall Cell	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 DrugCom(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	ClinicalTrials.gov (NCT03566576) Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
4	ClinicalTrials.gov (NCT03416517) Anlotinib and Irinotecan for Ewing Sarcoma
5	ClinicalTrials.gov (NCT04770688) Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
6	ClinicalTrials.gov (NCT04764084) Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
7	ClinicalTrials.gov (NCT03766490) Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
8	ClinicalTrials.gov (NCT03602027) Phase I Study of the Combination of Anlotinib With Gefitinib
9	ClinicalTrials.gov (NCT04967079) Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
10	ClinicalTrials.gov (NCT04080843) Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
11	ClinicalTrials.gov (NCT04566952) Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
12	ClinicalTrials.gov (NCT04157478) Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma
13	ClinicalTrials.gov (NCT04376073) Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
14	ClinicalTrials.gov (NCT05089643) Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
15	ClinicalTrials.gov (NCT04624711) Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
16	ClinicalTrials.gov (NCT04797806) Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
17	ClinicalTrials.gov (NCT04073550) Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
18	ClinicalTrials.gov (NCT04028778) Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC